Analysis of Electronic Health Records Reveals Medication-Related Interference on Point-of-Care Urine Drug Screening Assays.

Autor:	Ayala-Lopez N; Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, 1161 21st Ave South, Nashville, TN, 37232 USA., Colby JM; Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, 1161 21st Ave South, Nashville, TN, 37232 USA., Hughey JJ; Department of Biomedical Informatics, Vanderbilt University Medical Center, 2525 West End Ave, Nashville, TN, 37203 USA.
Jazyk:	angličtina
Zdroj:	Journal of analytical toxicology [J Anal Toxicol] 2022 Feb 14; Vol. 46 (1), pp. 99-102.
DOI:	10.1093/jat/bkaa179
Abstrakt:	Point-of-care (POC) urine drug screening (UDS) assays provide immediate information for patient management. However, POC UDS assays can produce false-positive results, which may not be recognized until confirmatory testing is completed several days later. To minimize the potential for patient harm, it is critical to identify sources of interference. Here, we applied an approach based on statistical analysis of electronic health record (EHR) data to identify medications that may cause false positives on POC UDS assays. From our institution's EHR data, we extracted 120,670 POC UDS and confirmation results, covering 12 classes of target drugs, along with each individual's prior medication exposures. Our approach is based on the idea that exposure to an interfering medication will increase the odds of a false-positive UDS result. For a given assay-medication pair, we quantified the association between medication exposures and UDS results as an odds ratio from logistic regression. We evaluated interference experimentally by spiking compounds into drug-free urine and testing the spiked samples on the POC device. Our dataset included 446 false-positive UDS results (presumptive positive screen followed by negative confirmation). We quantified the odds ratio of false positives for 528 assay-medication pairs. Of the six assay-medication pairs we evaluated experimentally, two showed interference capable of producing a presumptive positive: labetalol on the 3,4-methylenedioxymethamphetamine (MDMA) assay (at 200 μg/mL) and ranitidine on the methamphetamine assay (at 50 μg/mL). Ranitidine also produced a presumptive positive for opiates at 1,600 μg/mL and for propoxyphene at 800 μg/mL. These findings highlight the generalizability and the limits of our approach to use EHR data to identify medications that interfere with clinical immunoassays. (© The Author(s) 2020. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu